Ying Zhang1, Eric L Chang1. 1. Department of Radiation Oncology, Keck School of Medicine of USC, Norris Cancer Hospital and LAC+USC Medical Center, Los Angeles, CA, USA.
Abstract
PURPOSE: This study aims to perform a systematic review of published literature addressing outcomes related to postoperative stereotactic radiosurgery (SRS) delivered to the cavity of resected intracranial metastases. METHODS: A thorough literature search was performed on all reports published in English of SRS to the resection cavity after surgical resection, in patients who did not receive immediate whole brain radiotherapy (WBRT). RESULTS: 15 single-institution publications were identified which fit the search criteria. In 11 of the 13 studies that reported on number of lesions treated (85%), more than 50% of the patients had a single lesion. 11 publications (73%) reported the percentage of gross total resections (GTR) , which ranged from 68-100%. The predominant histology was non-small cell lung cancer. Modalities used included GammaKnife, CyberKnife, and linac-based radiosurgical platforms. Nine institutions (60%) added a margin to the post-surgical cavity. One year local control ranged between 74-91.5%. Distant brain recurrences occurred at a median of 53.8% of the time at a median of 7.8 months. Very few (<10%) patients developed symptomatic necrosis. Leptomeningeal disease incidence at recurrence was reported in four studies ranging from 4.2% to 25%, with 44.4% to 50% occurring in the posterior fossa. Salvage therapy included WBRT used 19-47% of the time at a median of 8months. CONCLUSION: Postsurgical SRS is a safe and effective modality that can be used to limit recurrences in the postoperative cavity when postoperative WBRT is omitted but does not address distant intracranial recurrences. Further investigation of its efficacy and toxicity is ongoing in a randomized control trial.
PURPOSE: This study aims to perform a systematic review of published literature addressing outcomes related to postoperative stereotactic radiosurgery (SRS) delivered to the cavity of resected intracranial metastases. METHODS: A thorough literature search was performed on all reports published in English of SRS to the resection cavity after surgical resection, in patients who did not receive immediate whole brain radiotherapy (WBRT). RESULTS: 15 single-institution publications were identified which fit the search criteria. In 11 of the 13 studies that reported on number of lesions treated (85%), more than 50% of the patients had a single lesion. 11 publications (73%) reported the percentage of gross total resections (GTR) , which ranged from 68-100%. The predominant histology was non-small cell lung cancer. Modalities used included GammaKnife, CyberKnife, and linac-based radiosurgical platforms. Nine institutions (60%) added a margin to the post-surgical cavity. One year local control ranged between 74-91.5%. Distant brain recurrences occurred at a median of 53.8% of the time at a median of 7.8 months. Very few (<10%) patients developed symptomatic necrosis. Leptomeningeal disease incidence at recurrence was reported in four studies ranging from 4.2% to 25%, with 44.4% to 50% occurring in the posterior fossa. Salvage therapy included WBRT used 19-47% of the time at a median of 8months. CONCLUSION: Postsurgical SRS is a safe and effective modality that can be used to limit recurrences in the postoperative cavity when postoperative WBRT is omitted but does not address distant intracranial recurrences. Further investigation of its efficacy and toxicity is ongoing in a randomized control trial.
Authors: Hideki Ogiwara; Kapila Kalakota; Sunpreet S Rakhra; Irene B Helenowski; Maryanne H Marymont; John A Kalapurakal; Minesh P Mehta; Robert B Levy; James P Chandler Journal: J Neurooncol Date: 2012-03-18 Impact factor: 4.130
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: David D Limbrick; Eriks A Lusis; Michael R Chicoine; Keith M Rich; Ralph G Dacey; Joshua L Dowling; Robert L Grubb; Eric A Filiput; Robert E Drzymala; David B Mansur; Joseph R Simpson Journal: Surg Neurol Date: 2008-04-18
Authors: David Mathieu; Douglas Kondziolka; John C Flickinger; David Fortin; Brendan Kenny; Karine Michaud; Sanjay Mongia; Ajay Niranjan; L Dade Lunsford Journal: Neurosurgery Date: 2008-04 Impact factor: 4.654
Authors: Neal Luther; Douglas Kondziolka; Hideyuki Kano; Seyed H Mousavi; Johnathan A Engh; Ajay Niranjan; John C Flickinger; L Dade Lunsford Journal: Neurosurgery Date: 2013-12 Impact factor: 4.654
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: John H Suh; Rupesh Kotecha; Samuel T Chao; Manmeet S Ahluwalia; Arjun Sahgal; Eric L Chang Journal: Nat Rev Clin Oncol Date: 2020-02-20 Impact factor: 66.675
Authors: Eduardo E Lovo; Leonel B Torres; Fidel J Campos; Victor E Caceros; Kaory E Barahona; Mario H Minervini; William A Reyes Journal: Cureus Date: 2019-08-24